Short answer
Inhibrx Biosciences, Inc. (INBX) filed an 8-K current report with the SEC on June 15, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA accepted ozekibart BLA for unresectable or metastatic conventional chondrosarcoma.
Inhibrx Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA accepted ozekibart BLA for unresectable or metastatic conventional chondrosarcoma
- No filing review issues identified, reducing near-term regulatory uncertainty
- PDUFA decision target set for April 14, 2027
- Potential approval milestone for INBRX-109 and validation of Inhibrx’s oncology pipeline
Item 8.01 · Other Events
- FDA accepted Inhibrx’s ozekibart BLA for unresectable or metastatic conventional chondrosarcoma
- No filing review issues identified, reducing near-term regulatory uncertainty
- PDUFA decision target set for April 14, 2027
- Regulatory milestone advances ozekibart toward potential commercialization in a serious cancer indication
Item EX-99.1 · Exhibit EX-99.1
- FDA accepted ozekibart’s BLA without filing review issues, setting an April 14, 2027 PDUFA decision date
- Registrational trial showed 52% lower progression-or-death risk, with median PFS 5.52 months versus 2.66 months for placebo
- Disease control rate reached 54% versus 27.5%, supporting potential approval in a disease with no approved systemic therapy
- Ozekibart could become Inhibrx’s first commercial product and the first FDA-approved systemic treatment for advanced chondrosarcoma
- Hepatic adverse events occurred in 11.8% versus 4.5% for placebo, highlighting a key approval and commercialization risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibrx Biosciences, Inc. 8-K filings
Get the next INBX 8-K as it lands
Follow INBX for push alerts, or ask the research agent what this filing means.